Bank of America Reiterates Buy on Pfizer

Bank of America reiterated its Buy rating on Pfizer PFE. In a research report published today, Bank of America states, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions that could enhance shareholder value, in our view. Pipeline progress and business development deals are also key drivers." At the moment, Bank of America has a price target of $25 on the company's stock. On Monday, Pfizer closed at $20.93. Its shares added 0.48% in today's pre-market trading, however, to climb to $21.03.